These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
586 related items for PubMed ID: 31000584
1. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors. Gålne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenström E, Sundlöv A, Trägårdh E. J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584 [Abstract] [Full Text] [Related]
8. The Influence of Long-Acting Somatostatin Analogs on 68 Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors. Chahid Y, Hashimi K, van de Garde EMW, Klümpen HJ, Hendrikse NH, Booij J, Verberne HJ. Clin Nucl Med; 2023 Sep 01; 48(9):757-762. PubMed ID: 37486312 [Abstract] [Full Text] [Related]
9. Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cherk MH, Kong G, Hicks RJ, Hofman MS. Cancer Imaging; 2018 Jan 24; 18(1):3. PubMed ID: 29361984 [Abstract] [Full Text] [Related]
10. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. J Nucl Med; 2011 Dec 24; 52(12):1864-70. PubMed ID: 22072704 [Abstract] [Full Text] [Related]
11. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors. Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S. J Nucl Med; 2024 Oct 01; 65(10):1591-1596. PubMed ID: 39266292 [Abstract] [Full Text] [Related]
18. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. J Nucl Med; 2010 Jun 01; 51(6):875-82. PubMed ID: 20484441 [Abstract] [Full Text] [Related]
19. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE. Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. J Nucl Med; 2020 Feb 01; 61(2):217-221. PubMed ID: 31302632 [Abstract] [Full Text] [Related]
20. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors. Menon BK, Kalshetty A, Bhattacharjee A, Basu S. Nucl Med Commun; 2020 Oct 01; 41(10):1095-1099. PubMed ID: 32732598 [Abstract] [Full Text] [Related] Page: [Next] [New Search]